Treatment costs of acute myocardial infarction in the Netherlands
about
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands.National trends in hospital length of stay for acute myocardial infarction in China.Role of the ECG in initial acute coronary syndrome triage: primary PCI regardless presence of ST elevation or of non-ST elevationA Novel Dietary Assessment Method to Measure a Healthy and Sustainable Diet Using the Mobile Food Record: Protocol and Methodology.A Modelling Approach to Estimate the Impact of Sodium Reduction in Soups on Cardiovascular Health in the Netherlands.Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the NetherlandsDeterminants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey.The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands.Costs and benefits of treatment of myocardial infarction.Comparison of the treatment practice and hospitalization cost of percutaneous coronary intervention between a teaching hospital and a general hospital in Malaysia: A cross sectional study.Medical costs in patients with heart failure after acute heart failure events: one-year follow-up study.
P2860
Q34004770-1FF9D989-BC3D-4AAC-980F-8484712E1B11Q35155123-11564101-67B5-4195-8B30-1772F21220C2Q35180304-5F03AA6F-2E37-4DC4-80C2-1E4FFEF451D7Q35337680-DD97C003-CE7E-4167-A834-A4C5260DB2D8Q35894992-0D31F6A9-82E5-4AC2-A95B-8FF01D2D40A1Q36102169-45E08695-1044-451F-9ED0-08AE516CD8D5Q36173045-172E8C0C-4191-4A8D-9762-30910BB33F9CQ37680408-F4EC888E-279D-4859-B3D6-ABC88C315EC8Q38321172-D2FBCF76-4BC5-49F0-8CD7-22B9AC76F424Q38380588-E3917198-C298-4AB8-9FC4-6134962573F0Q38610543-994AA757-4413-4760-8ED7-F65A9CB6F601Q40113333-E23BC4E0-6496-494F-AD40-EEC69A4FA3C4Q41618016-C040384C-937E-419F-B776-6BBDB330B1DDQ47619118-1D7EEE46-65AB-4755-A8B3-8BF4E0E37782
P2860
Treatment costs of acute myocardial infarction in the Netherlands
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Treatment costs of acute myocardial infarction in the Netherlands
@ast
Treatment costs of acute myocardial infarction in the Netherlands
@en
type
label
Treatment costs of acute myocardial infarction in the Netherlands
@ast
Treatment costs of acute myocardial infarction in the Netherlands
@en
prefLabel
Treatment costs of acute myocardial infarction in the Netherlands
@ast
Treatment costs of acute myocardial infarction in the Netherlands
@en
P2093
P2860
P1476
Treatment costs of acute myocardial infarction in the Netherlands
@en
P2093
L T Burgers
R R Soekhlal
W K Redekop
P2860
P2888
P304
P356
10.1007/S12471-013-0386-Y
P577
2013-05-01T00:00:00Z